ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Comparative disproportionality signals for methotrexate monotherapy versus methotrexate combined with hydroxychloroquine, leflunomide, or sulfasalazine in rheumatoid arthritis: newly highlighted signals evaluated using drug information safety profiles.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate (MTX) is the anchor conventional synthetic disease-modifying antirheumatic drug (csDMARD) in rheumatoid arthritis. Postmarketing safety patterns may differ between MTX monotherapy and MTX-based dual-csDMARD combinations. This study aimed to compare disproportionality signals for MTX alone versus MTX combined with hydroxychloroquine, leflunomide, or sulfasalazine and comparison with drug information safety profiles. A retrospective disproportionality study was conducted using a spontaneous reporting database across 2016Q1 to 2025Q2. Groups were MTX only (MTX as primary suspect) and MTX + hydroxychloroquine, leflunomide, or sulfasalazine (two drug reports with one primary suspect and one secondary suspect). Reporting odds ratios (RORs) were estimated at system organ class (SOC) and preferred term (PT) levels. Significant PTs were checked against drug information safety profiles. Time-to-onset (TTO) was summarized. A total of 148,315 reports were eligible. SOC signals were modest for MTX only, and highest for infections and infestations (ROR = 1.77) and blood and lymphatic disorders (ROR = 1.77). Combination cohorts showed strong musculoskeletal signals (ROR 8.13 to 9.64) and investigations (ROR = 3.25 to 3.72). Selected PT RORs included mucosal inflammation = 12.47, bone marrow failure = 12.83, and B-cell lymphoma = 13.94 in MTX only. Chondropathy reached 19.16 in MTX + leflunomide. Lip blister reached 17.02 and compartment syndrome 17.56 in MTX + sulfasalazine. Early TTO was seen for vomiting (median 22 days; 67% within 30 days) and mucosal inflammation (median 14 days; 58% within 30 days) in MTX only. Drug ineffective was delayed across groups, up to 1422 days in MTX + hydroxychloroquine. Strict exposure signal detection identified regimen-specific SOC, PT, and TTO patterns. Several significant PTs were not captured in drug information profiles and warrant follow-up.
Indexed as
Identifiers
41721120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.